Brainsway (NASDAQ:BWAY – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.07, Zacks reports. Brainsway had a return on equity of 12.51% and a net margin of 15.68%.The firm had revenue of $15.53 million for the quarter, compared to the consensus estimate of $14.63 million.
Here are the key takeaways from Brainsway’s conference call:
- BrainsWay delivered strong Q1 2026 results, with revenue up 35% year over year to $15.5 million, net income more than doubling to $2.3 million, and adjusted EBITDA rising 119% to $2.8 million.
- The company reported its 11th consecutive quarter of profitability, supported by expanding margins, disciplined cost control, and a recurring revenue model that continues to gain traction.
- Demand indicators improved, including 117 Deep TMS systems shipped in the quarter, a total install base of about 1,820 systems, and remaining performance obligations rising to $75 million, with most new contracts being multi-year agreements.
- Management highlighted reimbursement and adoption progress for both Deep TMS and the SWIFT protocol, including expanded payer coverage, growing interest from providers, and expectations for $40 million-$50 million of SWIFT-covered lives by year-end.
- The company remains focused on pipeline and strategic expansion, including an upcoming FDA filing for PTSD symptoms in MDD, ongoing alcohol use disorder trials, and additional minority investments in mental health networks and Neurolief’s ProlivRx platform.
Brainsway Stock Down 7.9%
Shares of NASDAQ:BWAY traded down $1.29 during midday trading on Friday, reaching $15.03. The company had a trading volume of 260,654 shares, compared to its average volume of 191,946. The business’s 50 day moving average price is $14.52 and its 200 day moving average price is $11.62. The stock has a market cap of $601.80 million, a PE ratio of 42.94 and a beta of 1.23. Brainsway has a 1-year low of $4.94 and a 1-year high of $17.35.
Institutional Trading of Brainsway
Wall Street Analyst Weigh In
Several research firms have issued reports on BWAY. HC Wainwright dropped their price target on Brainsway from $30.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, March 12th. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings raised Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, April 24th. Northland Securities set a $15.00 price target on Brainsway in a research note on Thursday, January 22nd. Finally, Zacks Research downgraded Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Monday. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.
Read Our Latest Research Report on BWAY
Brainsway Company Profile
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Read More
- Five stocks we like better than Brainsway
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
